retatrutide clinical trial results 2024 Retatrutide—A Game Changer in Obesity Pharmacotherapy VisualAbstract: Retatrutide reduces body weight
Description
PMID 40196945
doi: 10.1139/bcb-2021-0365 43 BudakMachnikGBudakRJabuzekKBodysABelowskiDet al
FDA approved Ozempic in December 2017 as an adjunct to diet and exercise for improving glycemic control in T2D
Tirzepatide is a dual agonist of GIP and GLP-1 receptors, acting in an integrated way across incretin pathways
In addition, other structures used were taken from PubChem
